Home/Filings/4/0001209191-12-012982
4//SEC Filing

Holveck David 4

Accession 0001209191-12-012982

CIK 0001100962other

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 5:22 PM ET

Size

14.7 KB

Accession

0001209191-12-012982

Insider Transaction Report

Form 4
Period: 2012-02-22
Holveck David
DirectorPresident & CEO
Transactions
  • Award

    2010 Stock Incentive Plan Performance Shares

    2012-02-22+52,834104,747 total
  • Award

    2010 Stock Incentive Plan Stock Options

    2012-02-22+173,940173,940 total
    Exercise: $34.70Exp: 2022-02-22Common Stock (173,940 underlying)
  • Award

    2010 Stock Incentive Plan Restricted Stock Units (RSU)

    2012-02-22+52,83491,768 total
Footnotes (7)
  • [F1]Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of Endo Pharmaceuticals Holdings Inc. common stock. These restricted stock units (RSUs) are generally exercisable 25% per year on each of February 22, 2013, February 22, 2014, February 22, 2015 and February 22, 2016. Upon vesting, we consider the underlying RSUs to be expired. Pursuant to the Endo Pharmaceuticals Executive Deferred Compensation Plan, on November 8, 2009, Mr. Holveck elected to defer receipt of all of these RSUs until February 1, 2016.
  • [F2]Pursuant to the Endo Pharmaceuticals Executive Deferred Compensation Plan, on November 8, 2009, Mr. Holveck elected to defer receipt of all of these RSUs until February 1, 2016.
  • [F3]These securities were granted to Mr. Holveck in consideration of his services as the President & Chief Executive Officer of Endo Pharmaceuticals Holdings Inc.
  • [F4]The performance shares vest upon the Company achieving certain financial targets.
  • [F5]Represents target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain company performance targets over a cumulative 3-year period, as determined by the Compensation Committee of the Board of Directors of Endo Pharmaceuticals Holdings Inc. The executive can earn between 0% and 200% of the target shares.
  • [F6]Representing the right to buy shares of common stock, par value $0.01 per share, of Endo Pharmaceuticals Holdings Inc.
  • [F7]These stock options are generally exercisable 25% per year on each of February 22, 2013, February 22, 2014, February 22, 2015 and February 22, 2016.

Issuer

ENDO PHARMACEUTICALS HOLDINGS INC

CIK 0001100962

Entity typeother

Related Parties

1
  • filerCIK 0001429993

Filing Metadata

Form type
4
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 5:22 PM ET
Size
14.7 KB